Sevaartinib tablets approved for marketing.
April 22, 2026
Source: drugdu
33
On April 21, according to the website of the National Medical Products Administration (NMPA), the NMPA has conditionally approved the marketing of the Class 1 innovative drug celvaartinib tablets (trade name: Herxinno) submitted by Bayer HealthCare Pharmaceuticals Inc. through the priority review procedure.This drug is indicated as monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy.
https://mp.weixin.qq.com/s/g4lHuTRty7BHotg4Y7M6hA
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Just now, Simcere Pharmaceutical received a notification for its “Lendibaimab” product! April 22, 2026
- Good news keeps coming! Six active pharmaceutical ingredients, including Ibrutinib, from Lunan Pharmaceutical have received approval for marketing in China. April 22, 2026
- Industry News | FDA Approves Merck’s Oral HIV Therapy! April 22, 2026
- Is the belief in Alzheimer’s disease Aβ “collapsed”? April 22, 2026
- Zai Lab’s stock price surged 40% in less than a month; Zoci may become a cornerstone drug. April 22, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
